Dr. Alicia K. Morgans

Dr. Alicia K. Morgans

Sep 3, 2025

Director of Adult Survivorship, Associate Professor of Medicine

Director of Adult Survivorship, Associate Professor of Medicine

Dana-Farber Cancer Institute, Harvard Medical School

Alicia Morgans, MD, MPH, is a Genitourinary Medical Oncologist, Director of the Adult Survivorship Program at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School. A clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. 

Dr. Morgans received her MD degree from the University of Pennsylvania School of Medicine in 2006 and her Master of Public Health (MPH) degree from Vanderbilt University School of Medicine in 2015. 

Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications. Her work has been funded by grants from the National Comprehensive Cancer Network, the Prostate Cancer Foundation, and the Department of Defense. She leads multiple therapeutic and quality-of-life focused clinical trials for prostate cancer patients. 

She is a member of the advanced and localized prostate cancer treatment guidelines committee of the American Urologic Association and a member of the cardio-oncology committee of the American Heart Association.  

Go To Session:

Dr. Artie Shelton

Dr. Artie Shelton

Sep 3, 2024

Prostate Cancer Survivor and PHEN Ambassador

Prostate Cancer Survivor and PHEN Ambassador

Colonel (ret) US Army Veteran, President / CEO of Shelton Professional Services

Artie L. Shelton, MD, Colonel (ret) U.S Army veteran, is President CEO of Shelton Professional Services. Dr. Shelton is a committed PHEN advocate and serves as PHEN’s Regional Coordinator for the Washington, D.C area. He is a 22-year prostate cancer survivor/warrior and advocate for the Prostate Health Education Network (PHEN). Dr. Shelton was appointed by Governor O’Malley to serve a six-year term as a member of the Maryland Council on Cancer Control and co-chaired writing the prostate chapter for the Maryland Comprehensive Cancer Control Plan Executive Summary. Dr. Shelton has served on the Department of Defense (DoD) Congressional Directed Medical Research Program (CDMRP) as a consumer reviewer/advocate and on the consumer work group.

Dr. Shelton states that during his person venture, with prostate cancer, he became aware of the magnitude of this disease that is impacting all men, but especially on African American men.

All health organizations must take PHEN’s example in their efforts to combat this disease and potentially cure it if diagnosed early. Faith-based and other organizations need to take advantage of their leadership roles and positions in society to raise public awareness in the fight against prostate cancer.

Go To Session:

Mr. Charles “Chuck” Christian

Mr. Charles “Chuck” Christian

Aug 21, 2023

Prostate Cancer Survivor, Owner, Former University of Michigan Football Player

Prostate Cancer Survivor, Owner, Former University of Michigan Football Player

Chuck Christian Designs

Chuck Christian played for the University of Michigan football team and took part in the 1977 – 1981 Rose Bowl. He was diagnosed with stage 4 prostate cancer in 2016, which had metastasized to his bones. Despite this late-stage disease, Charles “Chuck” Christian has survived prostate cancer with the help of various therapies. He is the owner of Chuck Christian Designs and lives in Randolph, Massachusetts.

Go To Session:

Mr. Art Cain

Mr. Art Cain

Aug 21, 2023

Prostate Cancer Survivor

Prostate Cancer Survivor

University of Georgia

Art Cain is the Continuing Education (CE) Director at the University of Georgia and a prostate cancer survivor who has clinical trial experience. His prostate cancer had metastasized to the bone, but he is currently doing well due to several medications received via a clinical trial, bone-strengthening drugs, and a healthy lifestyle.

He has taken part in the PANTHER trial, which combines two medicines known as abiraterone and enzalutamide which was distributed among one group of White men and a second group of Black men. The trial researchers assessed the racial disparity differences and outcomes in prostate cancer.

He is also a member of Cascade United Methodist Church in Atlanta and faithful member and contributor to the Men’s Usher Board at Cascade. Cain has enjoyed running his entire life and, to this day, will still take part in running 10K races. Art Cain lives in the Atlanta, Georgia area with his wife Gwen.

Go To Session:

Mr. Sherman Womack

Mr. Sherman Womack

Aug 17, 2023

Prostate Cancer Survivor

Prostate Cancer Survivor

Deacon, Metropolitan Baptist Church, Boston

Sherman Womack holds a leadership position as a Deacon at the Metropolitan Baptist Church of Boston, which was first opened in 1935. Furthermore, Sherman Womack is a prostate cancer survivor who is a member of PHEN’s Survivor Network.

In 2008 and 2018, he participated in PHEN Survivor Roundtable Discussions. At these roundtables, Sherman explained his own personal cancer journey and the outreach efforts he has participated in to spread prostate cancer awareness.

Sherman Womack has worked at the Lynn Fire Department and resides in Peabody, Massachusetts.

Go To Session:

Dr. Richard Lee

Dr. Richard Lee

Aug 17, 2023

Clinical Co-Director: Claire and John Bertucci Center for Genitourinary Cancers, Assistant Professor

Clinical Co-Director: Claire and John Bertucci Center for Genitourinary Cancers, Assistant Professor

Mass General Cancer Center, Harvard Medical School

After completing a bachelor’s and a master’s degree at Harvard, Richard Lee, MD, PhD, then completed his medical school (M.D.) and graduate school (Ph.D.) training at the Albert Einstein College of Medicine in the Bronx, New York. He came to Mass General Hospital (MGH) for internal medicine residency training and then completed a medical oncology fellowship through the Dana-Farber Cancer Institute/MGH joint program. During that time, he performed basic science research at the Whitehead Institute of MIT.

Go To Session: